CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer

According to GLOBOCAN 2018, lung cancer is the leading cause of new cancer cases and cancer-related deaths. Worldwide, 2.1 million new lung cancer cases and 1.8 million deaths were reported in 2018 [1]. More than 80% of these cases are Non-small cell lung cancer (NSCLC), and almost the same percentage of tumours are high stage (Stage III and IV) [2]. About 30-40% of stage IV NSCLC patients develop central nervous system (CNS) disease [3,4]. Overall, 1-5% of NSCLC patients have leptomeningeal (LM) involvement [5].

Source: Lung Cancer - August 4, 2020 Category: Cancer & Oncology Authors: Moushumi Suryavanshi, Jiten Jaipuria, Manoj Kumar Panigrahi, Neha Goyal, Rishu Singal, Anurag Mehta, Ullas Batra, DC Doval, Vineet Talwar Source Type: research